Intraoperative mannitol during robotic-assisted-laparoscopic partial nephrectomy
Tóm tắt
Mannitol is routinely used during partial nephrectomies due to its renoprotective properties. With minimally invasive techniques, the need for mannitol has been questioned. Robotic-assisted laparoscopic partial nephrectomy (RALPN) has been shown to decrease warm ischemia time, which may potentially minimize the benefit of mannitol. To date, no prospective, randomized, controlled trials have investigated the use of mannitol in only robotic procedures. We hypothesize that the intraoperative mannitol use during RALPN provides no statistically significant benefit for post-operative renal function outcomes. We conducted a randomized, controlled, double-blinded, single surgeon, prospective study to assess renal function after RALPN. Patients were randomized into a control group with intravenous normal saline infusion prior to clamping of the vessels or to an experimental group with an infusion of mannitol. Estimated glomerular filtration rate (eGFR) were obtained prior to the surgery as well as post operatively at 24 h, 1 week, and 30 days. Preoperative eGFR showed no statistical differences between the groups and evaluation of median percent change in eGFR after surgery did not indicate a statistical difference between the groups after RALPN. After prospective analysis of the change in post-operative renal function of randomized groups who received 12 g of mannitol following RALPN, we determined that infusion of mannitol does not provide significant improvement of maintenance of renal functions after RALPN. Based on our results, we recommend discontinuing routine use of mannitol during RALPN.
Tài liệu tham khảo
Cairns P (2010) Cancer Biomark 9(1–6):461–473. https://doi.org/10.3233/CBM-2011-0176
https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html.. Accessed 11 July 2017
Chow W, Devesa SS, Warren JL et al (1999) Rising incidence of renal cell carcinoma in the United States. JAMA 281:1628
Nicholas E, Power AC, Maschino et al (2012) Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. Urology 79(4):821–825
Volpe A, Cadeddu JA et al (2011) Contemporary management of small renal masses. Eur Urol 60(3):501–515
Cosentino M, Breda A et al (2012) The use of mannitol in partial and live donor nephrectomy: an international survey. World J Urol 31:977–982
Visweswaran P, Massin EK, Dubose TD Jr (1997) Mannitol-induced acute renal failure. J Am Soc Nephrol 8(6):1028–1033
Gelman S (1996) Does mannitol save the kidney? Anesth Analg 82(5):899–901
Hemmelgarn BR et al (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303(5):423
Spaliviero M, Power NE, Murray KS et al (2018) Intravenous mannitol versus placebo during partial nephrectomy in patients with normal kidney function: a double-blind, clinically-integrated, randomized trial. Eur Urol 73:53–59
Cooper CA, Shum CF, Bahler CD, Sundaram CP (2017) Intraoperative mannitol not essential during partial nephrectomy. J Endourol. https://doi.org/10.1089/end.2017.0415. (Epub ahead of print)
Joannidis M, Druml W, Forni LG et al (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. Intensive Care Med 36:392
Collins GM, Green RD, Boyer D, Halasz NA (1980) Protection of kidneys from warm ischemic injury. Dosage and timing of mannitol administration. Transplantation 29:83–84